---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-413254"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2026-10-05T13:00:06+00:00"
generated_at: "2026-10-12T14:47:22.718732+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# PMV Pharmaceuticals Appoints Matt Eckler to Board; Plans Q1 2027 NDA for Rezatapopt

## Summary
- Dr. Matthew Eckler was appointed to PMV Pharmaceuticals' board on October 1, 2026, with a term expiring at the 2029 annual meeting.
- Eckler is a Principal at Samsara BioCapital and previously worked at ArrowMark Partners and GMT Capital; he will receive $40,000 annual cash compensation.
- He received an initial stock option award for 84,000 shares and is expected to receive annual options for 42,000 shares under the outside director policy.
- PMV plans to submit an NDA for accelerated approval of rezatapopt in platinum-resistant/refractory ovarian cancer with TP53 Y220C mutation in Q1 2027.
- The PYNNACLE Phase 2 monotherapy portion completed enrollment; rezatapopt has FDA Fast Track and Orphan Drug designations.

## SEC filing metadata
- accession: 0001193125-26-413254
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2026-10-05T13:00:06+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000119312526413254/0001193125-26-413254-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000119312526413254/d174662d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-413254
- JSON: https://secwatch.observer/filing/0001193125-26-413254.json
- Plain text: https://secwatch.observer/filing/0001193125-26-413254.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.